Log on / register
Feedback | Support | My details
Clinical review: Drotrecogin alfa (activated) as adjunctive therapy for severe sepsis--practical aspects at the bedside and patient identification.
Laterre PF, Wittebole X
Crit Care 2003 Dec, 7:445-50
[Full text] [PubMed] [Related articles] [Cited on BioMed Central]


printer friendly 
to  [Help]

BioMed Central articles that cite the above article:

1.
37%37%


 Research    
Early drotrecogin alpha (activated) administration in severe sepsis is associated with lower mortality: a retrospective analysis of the Canadian ENHANCE cohort
Hodder RV, Hall R, Russell JA, Fisher HN, Lee B
Critical Care 2009, 13:R78 (20 May 2009)
 [Abstract] [Full text] [PDF] [PubMed] [Related articles]
2.
37%37%


 Review    
The safety profile of drotrecogin alfa (activated)
Fumagalli R, Mignini MA
Critical Care 2007, 11(Suppl 5):S6 (19 December 2007)
 [Full text] [PDF] [PubMed] [Related articles] [Cited on BioMed Central]
3.
37%37%


 Review    
Practical aspects of treatment with drotrecogin alfa (activated)
Camporota L, Wyncoll D
Critical Care 2007, 11(Suppl 5):S7 (19 December 2007)
 [Full text] [PDF] [PubMed] [Related articles] [Cited on BioMed Central]

You can also check ISI Web of Science for additional citations (subscription required)
printer friendly 
to  [Help]
Terms and Conditions Privacy statement Information for advertisers Jobs at BMC Contact us
© 1999-2009 BioMed Central Ltd unless otherwise stated. Part of Springer Science+Business Media.